SEC goes after crypto giants, Sequoia splits, LIV/PGA, Messi's deal + LIVE Q&A!

Friedberg opens this episode as a self-deprecating stand-in host, flagging up front that it will run short and that the back half splices in a live Q&A taped at Jason Calacanis's Launch Summit in Napa Valley. The framing matters because it tells listeners the episode is structurally unusual: a truncated news discussion bolted to a recorded audience segment rather than the usual four-way studio conversation.

Much of the cold open is banter rather than substance, but it does surface a recurring theme of the show's self-mythology: the besties as a traveling act. The riff about Calacanis parading them in front of limited partners he was supposedly meant to raise money from, and the gag about an LP who claimed never to have met her own general partner, is comedy, but it rests on a real dynamic the pod leans on constantly: these four are investors whose personal brands are entangled with their fundraising.

The segment also establishes who is present and in what state. Friedberg repeatedly notes that Chamath is drunk, having started on margaritas in the early afternoon, which is offered as color but also sets up his looser, more combative posture later in the Q&A. These are claims made in jest among friends, not reporting, and should be read as the show's trademark ribbing rather than literal fact.

The RFK Jr. discussion opens not with policy but with Chamath's irritation at the backlash he and Sacks drew for hosting a fundraiser for Robert F. Kennedy Jr. He frames the attacks as coming from low-accomplishment critics and makes the provocative claim that mediocre voices should not be allowed to speak, a rhetorical flourish that Friedberg immediately needles as sweeping away half the internet. This is personal grievance dressed as principle, and the hosts treat it that way.

These people are, like, the biggest impostor loser

Sacks reframes the appeal of RFK Jr. in issue terms rather than partisan ones. He argues that many Republicans respect Kennedy because he opposes censorship, favors free speech and civil liberties, resists what Sacks calls a surveillance state, and advocates peace over war. Notably, Sacks says he has personally encountered no pushback from his own Republican circle, which cuts against the premise that backing a Democrat is politically costly on the right.

The most concrete segment is Sacks's retelling of a Kennedy video shot at the border near Yuma, Arizona. The described scene: the physical wall ends, a line of migrants from around the world begins at that gap, people are bused inland by the government and handed court dates years out, then dispersed. Sacks's rhetorical thrust is a question about competence, not just policy: if the federal government can organize buses, why can it not close the gap in the wall. It is worth separating the vivid anecdote, which is Sacks's account of a campaign video, from the policy claim he builds on top of it.

Friedberg presses on the framing, noting that a border-hawk position is unusual for a Democrat and citing reporting, which he attributes to the New York Times or a major outlet covering the candidacy, that much of Kennedy's agenda reads like Republican talking points. Sacks's counter is that even most self-identified Democrats oppose a genuinely open border, so the real thing Kennedy is breaking is a press blackout on conditions at the border rather than Democratic consensus. This is an assertion about media coverage, offered without specific sourcing.

The vaccine thread is where the hosts are least careful and most divided internally. Sacks notes Kennedy's documented concerns about pre-COVID vaccines and explicitly declines to judge whether Kennedy is right, saying he does not know enough. He then asserts Kennedy is right about COVID vaccine inefficacy, invoking Bill Gates as having conceded the shots are short-acting and weak against variants. That characterization of Gates's position is the hosts' paraphrase, not a verified quote, and the leap from acknowledged waning efficacy to the blunter claim that the vaccine does not work is the hosts' own.

Chamath escalates the rhetoric, recasting the vaccine as a death-reduction shot and a revenue grab by big pharma dressed up in unscientific thinking. Crucially, the panel does not agree. Friedberg pushes back, and even the more sympathetic framing concedes the shot lowered death rates, which is the opposite of saying it did nothing. The disagreement is substantive: lowering mortality and failing to prevent infection are distinct claims, and the hosts blur and then partly untangle them in real time before Friedberg cuts the topic off to avoid a full vaccine debate.

Friedberg lays out the week's news in concrete terms. The SEC filed 13 charges against Binance entities and founder Changpeng Zhao, alleging operation of unregistered securities exchanges, broker-dealers and clearing agencies, misrepresentation of trading controls and oversight on the Binance US platform, and unregistered offer and sale of securities. The agency then sought a temporary restraining order to freeze Binance's US assets. Separately, it sued Coinbase over its exchange and staking programs, naming 13 listed assets as crypto asset securities, and Coinbase stock fell 12%.

Coinbase's position, relayed through Brian Armstrong, is that the company will not shut down staking and welcomes the fight as a way to force regulatory clarity. The hosts summarize Armstrong's broader grievance: that Coinbase repeatedly tried to register, that the SEC offered no workable mechanism to do so, and that the same agency approved Coinbase's IPO filing with full knowledge of the business model before later suing. That last point is the sharpest tension the episode identifies, a regulator blessing a public listing and then alleging the underlying business is unlawful.

we're proud to represent the industry in court to finally get some clarity around crypto rules

Chamath offers the episode's most structured analysis by rejecting the popular conspiracy framing first. He dismisses the Twitter narrative that governments are moving against crypto because it threatens fiat, calling it largely untrue, and instead attributes the crackdown to two mundane forces: an SEC division that failed to do its job earlier by letting crypto-exposed businesses go public, and post-FTX cover-your-ass enforcement driven partly by the optics of the agency's prior coziness with those firms.

From that premise Chamath predicts a sequencing of targets: exchanges first, then custodial services, no ETF approvals, and eventually staking services and the venture funds that accumulated founding coins to later sell. This is a forecast, not a description of filed actions, but it is internally consistent with his read that the agency is systematically working down the value chain from the largest actors.

Calacanis supplies the ideological frame. He argues technology's core promise is existential competition and that crypto explicitly set out to replace fiat currency, which is the government's domain alongside its military and its laws. His conclusion is that governments were never going to cede control, so a crackdown was predictable. He pairs this with limited sympathy: he distinguishes outright fraudsters dumping tokens on retail investors from builders pursuing genuine innovation, while conceding the innovation is real.

The segment closes by naming the regulator's own stated rationale through Gensler, that Americans already have electronic money and existing services and therefore do not need crypto, and that the SEC's statutory function is to protect investors. The hosts present this as the official justification without endorsing it, setting up the sharper dispute over whether investor protection or something more aggressive is driving the agency, which the conversation carries into the next segment.

Calacanis argues the whole dispute was avoidable. In his telling, both the SEC and the crypto firms could have treated tokens as securities and limited sales to accredited investors, the roughly top 5% of earners making over $200,000 a year. The firms chose instead to let anyone buy, which he says is simply not how the American system works. His proposed remedy is a bill he says just passed Congress and is headed to the Senate that would let the other 94% of Americans take a test, likened to a driver's license exam, to become accredited.